Array ( [0] => 23943 [1] => 23593 [2] => 23591 ) Array ( [0] => 23943 [1] => 23593 [2] => 23591 ) Array ( [0] => 21531 ) Array ( [0] => 21531 )

Last Updated: 09/03/2023

Development of novel anti-malaria drugs that block parasite invasion

Objectives

To develop drugs that prevent parasites from invading and proliferating in human blood which causes malaria.

Principal Institution

Burnet Institute, Australia

Principal Investigators / Focal Persons

Paul Gilson

Rationale and Abstract

Malaria is a devastating parasitic disease that kills over 400,000 people a year. Antimalarial drugs play a crucial role in helping eradicate malaria but of great concern is that parasites are becoming resistant to current drugs. We are developing drugs that prevent parasites from invading and proliferating in human blood which causes malaria. We are also discovering how the drugs work with the aim of greatly improving their performance towards clinical uptake.

Project Outputs

Article: PfATP4 inhibitors in the Medicines for Malaria Venture Malaria Box and Pathogen Box block the schizont-to-ring transition by inhibiting egress rather than invasion Article: The sulfonylpiperazine MMV020291 prevents red blood cell invasion by the malaria parasite Plasmodium falciparum through interference with actin-1/profilin dynamics

External reference

Project details

Thematic Categories

Drug-based Strategies
Product Development

Date

Jan 2021 — Dec 2023

Total Project Funding

$760,750

Funding Details

National Health and Medical Research Council (NHMRC) Australia, Australia